Arrowhead Pharmaceuticals, Inc.
ARWR
$82.63
-$2.48-2.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -319.96M | -300.91M | 202.27M | -1.63M | -148.42M |
| Total Depreciation and Amortization | 25.80M | 25.37M | 25.08M | 23.93M | 22.57M |
| Total Amortization of Deferred Charges | 1.42M | 657.00K | -- | -- | -- |
| Total Other Non-Cash Items | 191.18M | 168.54M | 184.55M | 175.49M | 119.62M |
| Change in Net Operating Assets | 42.49M | 70.04M | -72.59M | -18.24M | 28.08M |
| Cash from Operations | -59.06M | -36.31M | 339.31M | 179.55M | 21.85M |
| Capital Expenditure | -16.06M | -14.57M | -17.30M | -22.67M | -39.47M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -785.67M | -689.45M | -212.65M | -106.63M | -385.37M |
| Cash from Investing | -801.72M | -704.02M | -229.95M | -129.29M | -424.84M |
| Total Debt Issued | 703.16M | 710.26M | 10.26M | 10.26M | 399.10M |
| Total Debt Repaid | -117.89M | -134.51M | -268.31M | -201.63M | -201.63M |
| Issuance of Common Stock | 219.38M | 189.03M | 296.67M | 245.37M | 245.09M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -20.46M | -22.83M | 0.00 | 20.00M | 16.87M |
| Cash from Financing | 784.19M | 741.96M | 38.62M | 74.01M | 459.43M |
| Foreign Exchange rate Adjustments | 1.56M | 1.17M | -227.00K | -401.00K | 3.96M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -75.03M | 2.81M | 147.75M | 123.86M | 60.39M |